Lv1
80 积分 2023-05-18 加入
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
22天前
已完结
Diagnosis and Treatment of Metastatic Colorectal Cancer
23天前
已完结
Treatment sequencing in metastatic colorectal cancer
23天前
已完结
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial
25天前
已完结
Navigating the clinical progress of antibody-drug conjugates: Emerging opportunities and remaining challenges
1个月前
已完结
Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS
1个月前
已完结
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results
2个月前
已完结
Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma
2个月前
已完结
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
2个月前
已完结
RNAi-based drug design: considerations and future directions
2个月前
已完结
皖公网安备34019202002308
